Because the patents for brand-name carboplatin (Paraplatin) have expired, generic versions of this medication are available. In fact, once generic carboplatin products became available, the brand-name medicine was no longer sold. The FDA has determined that generic forms of carboplatin are equivalent to the brand-name drug, as evidenced by the "AP" rating.
Is There a Generic Version of Carboplatin?Carboplatin is a prescription chemotherapy medication approved for treating ovarian cancer. It is a platinum chemotherapy medication that is given intravenously (by IV). In addition to being a platinum analogue, it belongs to a larger group of chemotherapy drugs known as alkylating agents. Carboplatin kills cells (including cancer cells and normal cells) by causing abnormal linkages in DNA, the genetic material of cells. This is known as cross-linking.
Carboplatin was originally sold under the brand name Paraplatin® by Bristol-Myers Squibb. It was first approved by the U.S. Food and Drug Administration (FDA) in 1989. However, the patents for carboplatin have expired, and the medication is available in generic form.
In fact, Bristol-Myers Squibb has stopped making brand-name Paraplatin, probably due to the low demand for the brand-name product once the generic versions became available.
Is Generic Carboplatin as Good as Paraplatin?
All generic medications must undergo certain tests to compare them to brand-name medications. The FDA then looks at these tests to decide if the generics are equivalent to the brand-name medications and assigns a rating to each one.
An "AP" rating means that the FDA has determined that a generic medication is equivalent to a brand-name medication. All of the generic carboplatin products currently available have an "AP" rating, meaning they should be equivalent to Paraplatin. However, generic medications are allowed to have different inactive ingredients than the brand-name medication.